Key result
Tofacitinib therapy linked to acute coronary syndrome and multivessel CAD in a rheumatoid arthritis patient.
Why the study?
Tofacitinib has increasingly been linked with an increased risk of cardiovascular events.
Case Report (n=1)
This case report highlights the potential cardiovascular risk, specifically multivessel coronary artery disease, associated with tofacitinib use in a patient with rheumatoid arthritis.
Alerts clinicians to possible tofacitinib-related coronary risk in RA; hypothesis-generating case leaves open causality.
Tofacitinib is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme, which is used to treat several autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, idiopathic arthritis, and ulcerative colitis. JAKs are enzymes that play a key role in inflammatory and immune signaling pathways. The medication is particularly useful as it can be given orally. However, over time, there has been much data that links this drug with an increased risk of cardiovascular events. We present a case of a 73-year-old male with a history of RA and hypertension presenting to the hospital with typical cardiac chest pain. He was found to have ischemic EKG changes and elevated troponin levels. He then underwent cardiac catheterization, which revealed significant coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Zerihun et al. (2025) conducted a case report in Rheumatoid arthritis and multivessel coronary artery disease (n=1). Tofacitinib was evaluated. A 73-year-old male with rheumatoid arthritis and well-controlled hypertension developed acute coronary syndrome and multivessel coronary artery disease after two years of tofacitinib therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: